SCHEMBL23945771

SCHEMBL23945771

O=C1CCC(N2C(=O)c3c(OCCCOC4CCNCC4)cccc3C2O)C(=O)N1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 14/20 0.46
▸ DDB1 Q16531 9/20 0.46
▸ BRD4 O60885 1/20 0.42
▸ STAT3 P40763 1/20 0.38
▸ IKZF3 Q9UKT9 3/20 0.37
▸ MAP1LC3B Q9GZQ8 2/20 0.35
▸ CCNK O75909 1/20 0.35
▸ CDK12 Q9NYV4 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ CDK5 Q00535 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ OPRM1 P35372 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ TNF P01375 2/20 0.35
▸ IL1B P01584 1/20 0.35
▸ TBXA2R P21731 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19709449 0.83 CRBN (0.52) CRBNDDB1BRD4STAT3IKZF3
SCHEMBL21996714 0.81 DDB1 (0.67) CRBNDDB1STAT3IKZF3MAP1LC3B
SCHEMBL19618073 0.80 CRBN (0.66) CRBNDDB1BRD4STAT3IKZF3
SCHEMBL22507965 0.79 CRBN (0.58) CRBNDDB1IKZF3TNFIL1B
SCHEMBL22606726 0.79 CRBN (0.47) CRBNDDB1BRD4IKZF3ALDH1A1
SCHEMBL20759891 0.79 CRBN (0.44) CRBNDDB1BRD4IKZF3ALDH1A1
SCHEMBL30772319 0.78 CRBN (0.71) CRBNDDB1STAT3IKZF3MAP1LC3B
SCHEMBL30772326 0.78 CRBN (0.71) CRBNDDB1STAT3IKZF3MAP1LC3B
SCHEMBL29165809 0.78 CRBN (0.71) CRBNDDB1STAT3IKZF3MAP1LC3B
SCHEMBL22959649 0.78 CRBN (0.51) CRBNDDB1BRD4STAT3IKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885BRD4 132/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885DDB1 1267/4885BRD4 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback